MedPath
FDA Approval

CIDOFOVIR DIHYDRATE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
October 25, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Cidofovir(375 mg in 5 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Maiva Pharma Private Limited

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

AVET LIFESCIENCES PRIVATE LIMITED

725656438

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CIDOFOVIR DIHYDRATE

Product Details

NDC Product Code
23155-216
Application Number
ANDA202501
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
April 21, 2021
CidofovirActive
Code: JIL713Q00NClass: ACTIMQuantity: 375 mg in 5 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
© Copyright 2025. All Rights Reserved by MedPath